Cancer Biomarkers is a leading journal in the field of cancer research, aimed at the exploration and identification of novel biomarkers for cancer detection, prognosis, and therapy. Published by IOS PRESS in the Netherlands, this journal serves as a pivotal resource for those engaged in oncology, genetics, and molecular biology, facilitating access to cutting-edge research and advancements within these disciplines. In its ongoing mission since 2005, the journal has become an essential reference point, currently occupying a Q3 category in Cancer Research, Genetics, and Oncology, and a Q2 category in miscellaneous Medicine fields. With its commitment to high-quality peer-reviewed articles, Cancer Biomarkers satisfies the intellectual appetite of researchers, clinicians, and students alike, contributing significantly to the ever-evolving landscape of cancer biomarker discovery and application. Though currently not available as Open Access, the journal maintains a robust presence in academic circles, underscored by respectable Scopus rankings across relevant categories.

Biomarker Research is a leading open access journal published by BMC, dedicated to advancing the field of biomarker discovery and clinical application. Since its inception in 2013, this journal has become a crucial resource for researchers and professionals in biochemistry, clinical biochemistry, and molecular medicine, achieving a prestigious Q1 ranking in each category in 2023. With an E-ISSN of 2050-7771, it maintains a strong reputation for disseminating high-quality research and innovative findings that contribute to the understanding of disease mechanisms and the development of novel diagnostics and therapeutics. The journal is accessible to a global audience, ensuring that vital research is freely available to promote collaboration and accelerate scientific progress. Operating out of the United Kingdom, Biomarker Research plays a significant role in addressing some of the most pressing challenges in medical research, making it an essential resource for academics, clinicians, and industry professionals alike.

Clinical Proteomics is a leading open-access journal, published by BMC since 2011, that aims to advance the field of proteomics by providing a platform for the dissemination of original research, critical reviews, and technological advancements in the analysis of proteins and their roles in health and disease. With an ISSN of 1542-6416 and E-ISSN 1559-0275, this esteemed journal covers a broad scope, converging years of research from 2004 to 2024. As a distinguished publication, it holds a Q1 ranking in Clinical Biochemistry and Q2 in both Molecular Biology and Molecular Medicine, reflecting its significance in the scientific community. Clinical Proteomics' commitment to open access ensures that its content is readily available to researchers, professionals, and students worldwide, facilitating the exchange of knowledge and fostering collaborative efforts in proteomic studies. Situated in the United Kingdom, this journal plays a pivotal role in shaping the future of biomedical research, appealing to anyone keen on the integration of proteomics in clinical practice and molecular investigation.

Current Medical Science is a prominent academic journal dedicated to advancing knowledge in the fields of Medicine, Biochemistry, and Genetics. Published by SPRINGER with an ISSN of 2096-5230 and E-ISSN 2523-899X, this journal is based in China and serves as a vital resource for researchers, professionals, and students alike. With a focus on innovative research and emerging trends, Current Medical Science has established itself with an impactful presence, operating under Open Access guidelines to ensure wide dissemination of scientific findings. The journal's recognition is underscored by its impressive Scopus rankings, including a Q3 quartile placement in Biochemistry and Genetics as of 2023. It is noteworthy that the journal spans converged years from 2018 to 2024, providing a comprehensive platform for scholarly discussions and developments that drive the evolution of medical science. As it continues to publish influential research, Current Medical Science plays an essential role in bridging the gap between laboratory science and clinical application.

Communications Medicine is a leading journal in the interdisciplinary field of medical communications, published by SpringerNature. Dedicated to advancing the scientific exchange of knowledge, this journal aims to facilitate the dissemination of innovative research, pivotal findings, and critical discussions that shape patient care and healthcare practices globally. With a commitment to open-access publishing, Communications Medicine ensures that cutting-edge health research is easily accessible to professionals, researchers, and students alike, fostering collaborative efforts across various medical disciplines. Although the current impact factor and specific metrics such as HIndex and Scopus ranks are not available, the journal's reputation and association with SpringerNature, renowned for its robust academic publishing, solidify its importance as a valuable resource in the ever-evolving landscape of medical communications. Researchers interested in engaging with the latest advancements and contributing to the dialogue surrounding health technologies and methodologies will find this journal an essential platform for their work.

Proteomics Clinical Applications, published by Wiley-VCH Verlag GmbH, is a pivotal journal in the realm of Clinical Biochemistry, with an impressive track record since its inception in 2007, continuing its impactful contributions to 2024. With an ISSN of 1862-8346 and an E-ISSN of 1862-8354, this prestigious journal currently holds a commendable Q2 ranking in Clinical Biochemistry, situated at the 54th percentile among its peers within Scopus rankings. Dedicated to the advancement of proteomics and its applications in clinical settings, Proteomics Clinical Applications serves as a bastion for innovative research, fostering knowledge exchange among scientists, healthcare professionals, and students alike. Through its focus on novel methodologies and translational research, the journal aims to bridge the gap between laboratory findings and clinical practice, significantly impacting patient care and outcomes. Although not open access, its content is accessible through various academic databases, ensuring that vital research reaches its intended audience.

The Scandinavian Journal of Clinical & Laboratory Investigation is a premier publication in the fields of clinical biochemistry and laboratory medicine, published by Taylor & Francis Ltd in the United Kingdom. With an ISSN of 0036-5513 and E-ISSN 1502-7686, this journal has been a vital source of scholarly articles since its inception in 1949, and is set to celebrate over seventy-five years of contributing to scientific knowledge in 2024. Ranked in the Q2 category for both Clinical Biochemistry and Medicine (Miscellaneous), it holds a robust position within the Scopus rankings, with a commendable rank of 77/117 in its discipline. The journal is dedicated to advancing research by offering a platform for high-quality studies that explore the development and application of clinical and laboratory investigations, making it essential reading for researchers, practitioners, and students interested in the latest advances and methodologies in the field. Although it does not currently offer Open Access, a wealth of valuable research insights awaits readers within its pages, highlighting its crucial role in fostering communication and innovation in clinical sciences.

Byulleten Sibirskoy Meditsiny, published by the Siberian State Medical University, is a pivotal open-access journal in the field of Molecular Medicine, with its current edition indexed under the ISSN 1682-0363. Since its transition to open access in 2013, the journal aims to disseminate high-quality research and advancements in biomedical sciences, particularly focusing on molecular mechanisms and therapeutic interventions. Despite its relatively recent recognition in Molecular Medicine, where it ranks in the 6th percentile, the journal is dedicated to fostering knowledge exchange and collaboration among researchers, professionals, and students alike. With a modest impact factor and quarterly publication, Byulleten Sibirskoy Meditsiny is positioned to serve as a valuable resource for those engaged in the intricate realms of molecular biology, biochemistry, and general medicine, contributing to the broader scientific discourse in the Russian Federation and beyond.

Biomarkers in Medicine is a prominent academic journal dedicated to advancing the field of medical biochemistry and drug discovery. Published by Future Medicine Ltd in the United Kingdom, this journal aims to provide a platform for researchers, clinicians, and biotechnology professionals to share their findings on the critical role of biomarkers in diagnosis, treatment, and prognosis of various diseases. With a focus on high-quality, peer-reviewed research, Biomarkers in Medicine supports the dissemination of innovative approaches and therapeutic developments across its converged publication years from 2008 to 2024. Rated in the Q3 category for biochemistry (medical), clinical biochemistry, and drug discovery, it occupies a significant place in its field, attracting contributions that push the boundaries of knowledge and application. Although it does not offer open access, the journal remains committed to excellence and rigor in the representation of ground-breaking studies, making it an essential resource for scholars and professionals eager to stay at the forefront of biomarker research.

Cell Reports Medicine, published by Cell Press, represents a pivotal advancement in the open access landscape of biomedical research since its inception in 2020. With a dedicated focus on the intersection of medicine, biochemistry, genetics, and molecular biology, this journal has quickly established itself as a key resource, earning a remarkable Q1 ranking in these fields. Based in the United States, Cell Reports Medicine boasts impressive metrics, ranking #25 out of 636 in General Medicine and #18 out of 221 in Biochemistry, underscoring its influence and reach within the scientific community, with a notable 96th and 92nd percentile respectively. As a fully open access journal, it fosters global dissemination of knowledge, ensuring that groundbreaking research is readily available to researchers, professionals, and students alike. The journal not only promotes high-quality research but also aims to bridge the gap between molecular discoveries and clinical applications, making it an essential addition to any academic library or researcher's toolkit.